West Pharmaceutical Services, INYSE: WST
Health Care · Health Care Supplies
$300.73
+1.05%
Vol: 480K
Research Digest
Friday, May 1, 2026
West Pharmaceutical record Q1 with 21% sales growth, 56% diluted EPS surge and Strong Buy upgrade
West Pharmaceutical Services delivered record Q1 2026 results with net sales of $844.9 million (+21.0%, organic +15.3%) and diluted EPS of $1.92 (+56.1%). Adjusted diluted EPS increased 46.9% to $2.13. Zacks upgraded to Strong Buy rank. Citi raised price target to $400 from $375, Barclays to $310 from $275. Announced $112.5 million SmartDose 3.5mL deal with AbbVie expected to close mid-2026.
Previous Market Intelligence
13 daysApr 30West Pharmaceutical reported Q1 2026 EPS of $1.92, up 56.1%, and upgraded to Strong Buy with price target raised 10% to $350 on strong GLP-1 driven growth.Positive▶
West Pharmaceutical reported strong Q1 2026 results with net sales of $844.9 million, up 21.0% with 15.3% organic growth. Diluted EPS increased 56.1% to $1.92 and adjusted EPS increased 46.9% to $2.13, beating estimates by 15%. The company was upgraded to Strong Buy with a 10% price target increase to $350. West also completed the sale of SmartDose manufacturing and supply rights to AbbVie for $112.5 million. Insider selling occurred on April 29 with senior VP selling approximately $859,753 in shares.
Apr 29West Pharmaceutical Q1 2026 net sales up 21% to $844.9M with diluted EPS of $1.92 (+56.1%); upgraded to Strong BuyPositive▶
West Pharmaceutical Services reported Q1 2026 net sales of $844.9 million, up 21.0% with 15.3% organic growth. Diluted EPS of $1.92 increased 56.1% and adjusted-diluted EPS of $2.13 increased 46.9%, beating analyst expectations by 15%. The company reached agreement to sell SmartDose 3.5mL manufacturing and supply rights to AbbVie for $112.5M, expected to close mid-2026. Analysts upgraded to Strong Buy with 10% price target increase to $350, and announced $0.22 cash dividend with ex-date of April 29.
Apr 16West Pharmaceutical Q1 earnings call April 23; Dublin facility expansion complete with 165000 sq ft capacity.Mixed▶
West Pharmaceutical Services is preparing for its Q1 2026 earnings call on April 23, 2026, after a year of mixed performance. The company announced a 165,000 square foot expansion at its Dublin facility in March 2026 designed to meet growing demands for high-volume treatments including diabetes and obesity therapies. West agreed to sell manufacturing and supply rights for SmartDose 3.5mL On-Body Delivery System to AbbVie for $112.5 million, with closing expected mid-2026. CEO Eric Green announced retirement plans in March 2026. The company declared a $1 billion share repurchase program in February 2026 and announced a quarterly dividend of $0.22 with ex-date April 29, 2026.
Apr 15West Pharmaceutical CEO Eric Green to retire in H2 2026; company issues positive 2026 guidance with 5-7% organic growth.Positive▶
West Pharmaceutical reported strong Q4 2025 results with EPS of $2.04 vs $1.84 forecast and revenue of $805M up 7.5% YoY. Issued positive 2026 guidance projecting revenue of $3.215-3.275B with 5-7% organic growth. CEO Eric Green announced plans to retire in H2 2026. The company launched a $1B share repurchase program. Q1 2026 earnings call scheduled April 23.
Apr 14Q1 2026 earnings due April 23 with $1B buyback and dividend increase announced.Positive▶
West Pharmaceutical Services announced a $0.22 quarterly dividend and new $1 billion share buyback program. The company is scheduled to report Q1 2026 results on April 23 before market open, with expectations of 15.9% EPS growth year-over-year. West also launched the ROSA Synchrony prefillable syringe system for biologics and vaccines.
Apr 13West Pharmaceutical scheduled Q1 2026 earnings for April 23 with expectations of 15.9% EPS growth year-over-year.Positive▶
West Pharmaceutical Services announced Q1 2026 earnings release on April 23, 2026. The company authorized a $1 billion share buyback program in February and declared $0.22 quarterly dividend payable May 6, 2026. West generated $3.07 billion in net sales in fiscal 2025.
Apr 10West Pharmaceutical Services scheduled Q1 2026 earnings call for April 23; company declares $0.22 quarterly dividend.Neutral▶
West Pharmaceutical Services announced first-quarter 2026 earnings release on April 23, 2026 before market open, with conference call at 8:00 a.m. Eastern Time. The company declared a $0.22 per share regular quarterly dividend payable May 6, 2026. No major overnight news or trading activity reported.
Apr 9West Pharma CEO retiring; Dublin facility expansion for injectable therapies launchedPositive▶
West Pharmaceutical CEO Eric M. Green plans retirement as President/CEO/Chair once successor hired (expected H2 2026). Company opened 165k sq ft Dublin expansion March 31 targeting high-volume diabetes/obesity treatments. $1B share repurchase program announced Feb 17. FY2025 revenue $3.07B (+6.25% YoY). Dividend raised; ex-date April 29 at $0.22/share. UBS cut target to $340 from $355 (Feb 13). Strong fundamentals despite transition; analysts optimistic on margins post-expansion.
Apr 8West Pharmaceutical declares $0.22 quarterly dividend; Q1 2026 earnings April 22.Neutral▶
WST declared $0.22 quarterly dividend payable May 6. Expanding Dublin facility for high-volume injectables. Stock between $245.92-$252.24. Q1 earnings April 22.
Apr 7West Pharmaceutical Expands Dublin Facility, CEO to Retire, New $1B Share Repurchase ProgramNeutral▶
West announced new 165,000 sq ft Dublin expansion to support high-volume injectables including GLP-1 diabetes treatments. CEO Eric Green plans retirement in H2 2026 (successor search underway). New $1B share repurchase program authorized. Q2 2025 revenue $804.6M (up 7.7% YoY), exceeding estimates by 2.1%. FY 2025 revenue guidance $3.07B (+0.5% above estimates). Dividend of $0.22 announced (ex-date April 29, 2026). WST up 1.04% weekly, down 2.82% monthly.
Apr 6West Pharmaceutical expanded Dublin facility and divested SmartDose assets to AbbVie for $112.5M.Positive▶
West Pharma announced 165,000 sq ft Dublin facility expansion on March 31, 2026 to support high-volume injectable therapies. CEO Eric Green announced retirement plans pending successor search. Company divested SmartDose 3.5mL manufacturing rights to AbbVie for $112.5M (closing mid-2026). Strong Q4 results with revenue beat and $1B share repurchase program announced in February 2026.
Apr 3West Pharmaceutical approved $1 billion share buyback and increased quarterly dividend to $0.22, while AbbVie agreed to acquire SmartDose facility for $112.5 million.Positive▶
West Pharmaceutical Services announced board approval for $1 billion share repurchase program with no expiration date and declared quarterly dividend of $0.22 per share payable May 6, 2026. The company reported Q4 2025 earnings of $2.04 per share, beating consensus of $1.83, with revenue of $805 million versus expected $795.70 million. AbbVie acquisition of Tempe, Arizona facility and associated intellectual property is expected to close mid-2026. FY 2026 guidance set at $7.85-$8.20 EPS.
Apr 2West Pharmaceutical Services opened a 165,000 sq ft Dublin facility on March 31 to support high-volume injectable therapies including GLP-1 treatments.Positive▶
West Pharmaceutical Services opened a 165,000 sq ft facility at its Damastown, Dublin site on March 31, 2026, expanding capacity for GLP-1 treatments. CEO Eric Green announced plans to retire in H2 2026. The company announced a $1B share repurchase program in February 2026 and reaffirmed 2026 guidance in March. Q3 2025 sales rose 7.7% to $804.6M.
Sector Peers
| Company | Price | Day | 1M | Fwd P/E | Beta | Mkt Cap |
|---|---|---|---|---|---|---|
| WSTWEST | $300.73 | +1.05% | +15.9% | 31.1x | 1.15 | $21.0B |
| ALGNALIGN | $178.92 | +1.65% | +2.4% | 14.2x | 1.81 | $12.6B |
| COOCOOPER | $62.34 | -0.89% | -10.5% | 12.5x | 1.07 | $12.3B |
| LLYELI | $964.50 | +3.20% | +0.8% | 22.2x | 0.50 | $834.9B |
| JNJJOHNSON | $227.78 | -0.90% | -4.6% | 18.1x | 0.33 | $553.3B |
| ABBVABBVIE | $207.05 | -2.02% | +2.2% | 13.1x | — | $373.8B |
Key Fundamentals
RSI (14-Day)
52-Week Range
Moving Averages
Price above both MAs — bullish structure.